Resource Library

Whitepapers

Streamlining single-use assemblies in the bulk-fill step of downstream processing

Streamlining single-use assemblies for biopharma companies in the bulk-fill step of downstream processing


Single-use systems for downstream manufacturing are effective in reducing contamination risks during the bulk fill stage. However, due to its complexity, streamlining a single-use system has a lot of challenges for validation.

 

In this whitepaper, we share insights on optimizing a standardized single-use system for the bulk fill process to enhance reliability and cost-effectiveness. 


The current state of single-use technology in the biopharma industry


Although single-use (SU) systems have existed since the early 1980s, their widespread adoption into biomanufacturing is still limited for various reasons. One significant challenge is the lack of industry-wide standards, as suppliers of SU components prefer to offer differentiated rather than standardized SU products to consumers. Integrating single-use assemblies in bioprocessing, including in downstream processing, can greatly benefit suppliers and manufacturers despite the complex and challenging process of changing validated production assemblies. By allowing faster turnaround times between process runs and greater adaptability to different client projects, SU assemblies can significantly improve efficiency, ultimately leading to lower costs.


 

Key benefits of standardizing single-use components include:

 

  • Improved cost-effectiveness: Standardizing single-use technology can significantly reduce inventory stocks at the manufacturing facility without risking supply discontinuation. 
  • Simplified documentation: Standardizing SU components can simplify the documentation process, saving work hours and reducing the need for additional procedures.
  • Enhanced reliability: Standardizing aseptic single-use assemblies improves the robustness, reliability, and predictability of the process.

 

Streamlining single-use assemblies for biopharma companies in the bulk-fill step of downstream processing


Single-use systems for downstream manufacturing are effective in reducing contamination risks during the bulk fill stage. However, due to its complexity, streamlining a single-use system has a lot of challenges for validation.

 

In this whitepaper, we share insights on optimizing a standardized single-use system for the bulk fill process to enhance reliability and cost-effectiveness. 


The current state of single-use technology in the biopharma industry


Although single-use (SU) systems have existed since the early 1980s, their widespread adoption into biomanufacturing is still limited for various reasons. One significant challenge is the lack of industry-wide standards, as suppliers of SU components prefer to offer differentiated rather than standardized SU products to consumers. Integrating single-use assemblies in bioprocessing, including in downstream processing, can greatly benefit suppliers and manufacturers despite the complex and challenging process of changing validated production assemblies. By allowing faster turnaround times between process runs and greater adaptability to different client projects, SU assemblies can significantly improve efficiency, ultimately leading to lower costs.


 

Key benefits of standardizing single-use components include:

 

  • Improved cost-effectiveness: Standardizing single-use technology can significantly reduce inventory stocks at the manufacturing facility without risking supply discontinuation. 
  • Simplified documentation: Standardizing SU components can simplify the documentation process, saving work hours and reducing the need for additional procedures.
  • Enhanced reliability: Standardizing aseptic single-use assemblies improves the robustness, reliability, and predictability of the process.

 

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Interests
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION